Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Ophthalmology

Treatment Strategy and Standard of Care for AKC

At a Glance

Atopic keratoconjunctivitis (AKC) is managed through a stepped approach. Treatment starts with environmental controls and artificial tears, progresses to topical steroids for acute flares, and relies on calcineurin inhibitors like tacrolimus for long-term maintenance to prevent vision loss.

Managing atopic keratoconjunctivitis (AKC) requires a “stepped” approach. Because the condition is chronic and potentially sight-threatening, the goal of treatment is to move from simply relieving symptoms to actively controlling the immune response while protecting the eye from long-term damage [1][2].

The Stepped Approach to Care

For most patients, treatment begins with foundational care and moves to more intensive therapies as needed:

  • Level 1: Foundational Support. This includes environmental triggers management. This means taking practical steps at home, such as using HEPA air purifiers, washing bedding in hot water weekly to avoid dust mites, and managing indoor humidity [3]. It also involves frequent use of preservative-free artificial tears and cold compresses to soothe the ocular surface [1][4].

    • CRITICAL DIRECTIVE: Do Not Rub Your Eyes. Eye rubbing is the single most significant behavioral trigger that causes keratoconus (thinning of the cornea) to progress [5][6]. When the urge to rub strikes, immediately apply a cold compress or flush your eyes with chilled, preservative-free artificial tears instead.
    • Eyelid Hygiene: Practicing regular eyelid hygiene with gentle lid scrubs helps manage the high levels of Staphylococcus aureus bacteria that live on the eyelids of AKC patients, which prevents secondary infections [7][8].

  • Level 2: Standard Relief. If symptoms persist, doctors often prescribe antihistamines or mast cell stabilizers (drops that prevent the release of inflammatory chemicals) [1][2].

  • Level 3: Managing Flares. Topical corticosteroids (steroid drops) are the most effective way to quickly shut down a severe inflammatory flare [1][2].

  • Level 4: Long-Term Maintenance (Steroid-Sparing Mainstays). To avoid the side effects of prolonged steroid use, specialists often prescribe calcineurin inhibitors, such as tacrolimus or cyclosporine [9][10]. These do not replace Level 3 steroids for acute flares, but they are used as a long-term bridge to maintain a calm eye environment and prevent flares from returning, reducing the need for steroids overall [11][1].

Pro Tip for Using Eye Drops: If you are prescribed multiple types of eye drops (e.g., artificial tears, steroids, and tacrolimus), always wait 5 to 10 minutes between putting each one in. This ensures the first drop is fully absorbed and not washed out by the next one.

The Steroid Challenge

While corticosteroids are powerful, they are generally not intended for long-term daily use in AKC. Prolonged use of steroid eye drops carries significant risks, including:

  • Glaucoma: An increase in intraocular pressure (the pressure inside the eye) that can damage the optic nerve [2][1].
  • Cataracts: A clouding of the eye’s natural lens that blurs vision [2][1].

When Topicals Aren’t Enough

For severe cases where drops are not sufficient, your medical team may look at systemic (body-wide) options:

  1. Treating the Eczema: Because AKC is so closely tied to your skin, systemic treatments for atopic dermatitis—such as oral immunosuppressants or biologics—can sometimes help stabilize the eyes, though this is not always a guaranteed fix [12][13].
  2. Systemic Immunosuppressants: Medications that dampen the entire immune system may be used to prevent permanent visual disability in the most severe cases [14][15].
  3. JAK Inhibitors: Newer systemic medications called JAK inhibitors (e.g., upadacitinib) are currently being explored for their potential to reduce ocular inflammation in patients with severe atopic disease [16][17].

Surgical Interventions for Advanced AKC

If chronic inflammation leads to structural damage of the eye, surgery may be necessary:

  • Amniotic Membrane Transplantation (AMT): A piece of specialized tissue is placed over the eye to act as a “biological bandage,” promoting the healing of non-healing corneal ulcers [8][18].
  • Corneal Transplants: This may involve Penetrating Keratoplasty (PK) (a full-thickness transplant) or Deep Anterior Lamellar Keratoplasty (DALK). DALK is often preferred for conditions like keratoconus because it leaves your innermost layer of the cornea intact, which significantly reduces the risk of your body rejecting the transplant [19][20].

Success in these surgeries depends heavily on achieving ocular surface homeostasis—a stable, calm eye environment—before the procedure takes place [21][15].

Common questions in this guide

Why is eye rubbing dangerous if I have AKC?
Eye rubbing is a major behavioral trigger that causes keratoconus, or thinning of the cornea, to progress. If you feel the urge to rub your eyes, you should immediately use a cold compress or flush your eyes with chilled, preservative-free artificial tears instead.
Why can't I use steroid eye drops long-term for my AKC?
Prolonged use of corticosteroid eye drops significantly increases your risk of developing glaucoma, which can damage the optic nerve, and cataracts, which cloud your vision. They are typically reserved for quickly calming severe inflammatory flares.
What are steroid-sparing therapies for AKC?
Steroid-sparing medications, such as tacrolimus or cyclosporine drops, are used for long-term maintenance. They help keep the eye environment calm and prevent flares without the severe side effects associated with daily, long-term steroid use.
How should I apply multiple types of eye drops?
If you are prescribed multiple drops, you should always wait 5 to 10 minutes between applying each one. This ensures the first drop is fully absorbed by the eye and is not washed out by the second drop.
Can treating my severe eczema help my eye symptoms?
Yes. Because AKC is closely linked to your skin health, systemic treatments for atopic dermatitis can sometimes help stabilize your eye condition. However, this is not a guaranteed solution and requires coordinated monitoring by your medical team.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Am I currently a candidate for 'steroid-sparing' therapies like tacrolimus or cyclosporine?
  2. 2.How often do we need to check my intraocular pressure to monitor for steroid-induced glaucoma?
  3. 3.Is my underlying atopic dermatitis (eczema) stable enough to support the healing of my eyes?
  4. 4.If we consider surgery like AMT, what is the plan for managing my ocular surface inflammation before and after the procedure?
  5. 5.What are the signs that my current topical treatment is no longer sufficient and we need to consider systemic options?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    Pharmacotherapeutic management of atopic keratoconjunctivitis.

    Hossain IT, Sanghi P, Manzouri B

    Expert opinion on pharmacotherapy 2020; (21(14)):1761-1769 doi:10.1080/14656566.2020.1786534.

    PMID: 32602382
  2. 2

    Ocular itch associated with allergic conjunctivitis: latest evidence and clinical management.

    Ackerman S, Smith LM, Gomes PJ

    Therapeutic advances in chronic disease 2016; (7(1)):52-67 doi:10.1177/2040622315612745.

    PMID: 26770669
  3. 3

    Air pollution significantly associated with severe ocular allergic inflammatory diseases.

    Miyazaki D, Fukagawa K, Fukushima A, et al.

    Scientific reports 2019; (9(1)):18205 doi:10.1038/s41598-019-54841-4.

    PMID: 31796815
  4. 4

    Emerging Therapeutics for Ocular Surface Disease.

    Bielory L, Schoenberg D

    Current allergy and asthma reports 2019; (19(3)):16 doi:10.1007/s11882-019-0844-8.

    PMID: 30815751
  5. 5

    Association between atopic keratoconjunctivitis and the risk of keratoconus.

    Weng SF, Jan RL, Wang JJ, et al.

    Acta ophthalmologica 2021; (99(1)):e54-e61 doi:10.1111/aos.14509.

    PMID: 32567209
  6. 6

    Epidemiological Association Between Systemic Diseases and Keratoconus in a Korean Population: A 10-Year Nationwide Cohort Study.

    Lee HK, Jung EH, Cho BJ

    Cornea 2020; (39(3)):348-353 doi:10.1097/ICO.0000000000002206.

    PMID: 31764280
  7. 7

    Transcriptome profiling of refractory atopic keratoconjunctivitis by RNA sequencing.

    Matsuda A, Asada Y, Suita N, et al.

    The Journal of allergy and clinical immunology 2019; (143(4)):1610-1614.e6 doi:10.1016/j.jaci.2018.11.007.

    PMID: 30471305
  8. 8

    Atopic keratoconjunctivitis with corneal ulcer. Case report.

    Zemba M, Burcea M, Camburu G

    Romanian journal of ophthalmology 2016; (60(3)):200-206.

    PMID: 29450349
  9. 9

    The efficacy of 0.1% tacrolimus ophthalmic suspension in the treatment of severe atopic keratoconjunctivitis.

    Yazu H, Shimizu E, Aketa N, et al.

    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2019; (122(4)):387-392.e1 doi:10.1016/j.anai.2019.01.004.

    PMID: 30639466
  10. 10

    Long-term outcomes of 0.1% tacrolimus eye drops in eyes with severe allergic conjunctival diseases.

    Yazu H, Fukagawa K, Shimizu E, et al.

    Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 2021; (17(1)):11 doi:10.1186/s13223-021-00513-w.

    PMID: 33522964
  11. 11

    Evaluation of Clinical Efficacy and Safety of Prolonged Treatment of Vernal and Atopic Keratoconjunctivitis Using Topical Tacrolimus.

    Hirota A, Shoji J, Inada N, et al.

    Cornea 2022; (41(1)):23-30 doi:10.1097/ICO.0000000000002692.

    PMID: 34870621
  12. 12

    Atopic keratoconjunctivitis: A diagnostic dilemma-a case report.

    Li A, Li S, Ruan F, Jie Y

    Medicine 2018; (97(16)):e0372 doi:10.1097/MD.0000000000010372.

    PMID: 29668589
  13. 13

    Emerging concepts in atopic dermatitis and atopic keratoconjunctivitis.

    Jafari K, Calder VL

    Current opinion in allergy and clinical immunology 2025; (25(5)):388-394 doi:10.1097/ACI.0000000000001102.

    PMID: 40767400
  14. 14

    Systemic interventions for severe atopic and vernal keratoconjunctivitis in children and young people up to the age of 16 years.

    Kim SE, Nowak V, Quartilho A, et al.

    The Cochrane database of systematic reviews 2020; (10()):CD013298 doi:10.1002/14651858.CD013298.pub2.

    PMID: 33084033
  15. 15

    Management of advanced ocular surface disease in patients with severe atopic keratoconjunctivitis.

    Jabbehdari S, Starnes TW, Kurji KH, et al.

    The ocular surface 2019; (17(2)):303-309 doi:10.1016/j.jtos.2018.12.002.

    PMID: 30528292
  16. 16

    Janus kinase inhibitors are effective in atopic keratoconjunctivitis treatment and not only in managing dupilumab-induced ocular adverse events.

    Bendoukha Y, Jacob B, Muraine M, et al.

    The British journal of dermatology 2025; doi:10.1093/bjd/ljaf424.

    PMID: 41152011
  17. 17

    Dupilumab-associated ocular surface disease or atopic keratoconjunctivitis not improved by dupilumab? Upadacitinib may clarify the dilemma: A case report.

    Galluzzo M, Tofani L, Spelta S, et al.

    Skin health and disease 2024; (4(3)):e354 doi:10.1002/ski2.354.

    PMID: 38846697
  18. 18

    Amniotic membrane transplantation: Current indications in a tertiary eye hospital of eastern Nepal.

    Hamal D, Singh SK, Lamichhane B, et al.

    Nepalese journal of ophthalmology : a biannual peer-reviewed academic journal of the Nepal Ophthalmic Society : NEPJOPH 2016; (8(16)):151-160 doi:10.3126/nepjoph.v8i2.17004.

    PMID: 28478469
  19. 19

    Surgical outcomes of perforated and unperforated corneal descemetocele.

    Ozdemir ES, Burcu A, Akkaya ZY, Ornek F

    International ophthalmology 2018; (38(1)):327-335 doi:10.1007/s10792-017-0472-z.

    PMID: 28224301
  20. 20

    Atopic keratoconjunctivitis: long-term results of medical treatment and penetrating keratoplasty.

    Koçluk Y, Yalniz-Akkaya Z, Burcu A, Örnek F

    Arquivos brasileiros de oftalmologia 2016; (79(6)):376-379 doi:10.5935/0004-2749.20160107.

    PMID: 28076564
  21. 21

    Ocular involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis: A review of current management and changing trends.

    Akgun Z, Can GD, Selver OB

    Indian journal of ophthalmology 2025; (73(12)):1711-1722 doi:10.4103/IJO.IJO_1119_25.

    PMID: 41288622

This page provides educational information on atopic keratoconjunctivitis (AKC) treatment options. Always consult with your ophthalmologist before starting, stopping, or changing your eye drop regimen.

Get notified when new evidence is published on Atopic keratoconjunctivitis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.